340 results about "Nucleoside" patented technology

The present invention provides a method for producing ribose-1-phosphate that is simple and yields improved efficiency. [Solution] A method for producing ribose-1-phosphate, comprising a contact step to produce ribose-1-phosphate and hypoxanthine by contacting inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium in a reaction solution containing inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium, wherein in the contact step, the hypoxanthine is present in an amount exceeding the saturation concentration relative to the medium.

The invention relates to an anti-aging capsule compounded by PQQ and mitochondrial nutrients, and discloses an anti-aging capsule which is prepared by synergistically compounding a plurality of mitochondrial nutrients according to a scientific proportion and supplementing high-purity raw materials and slow-release dosage forms to realize energy metabolism activation and anti-oxidation synergistic intervention. Therefore, the anti-aging capsule systematically delays aging through multi-target regulation and control of mitochondrial functions. The capsule is characterized by comprising the following components in parts by weight: 1-20 mg of pyrroloquinoline quinone disodium salt (PQQ), 20-100 mg of coenzyme Q10, 50-200 mg of L-carnitine tartrate, 10-100 mg of alpha-lipoic acid, 50-300 mg of nicotinamide mononucleotide (NMN) or nicotinamide nucleoside (NR), and 10-50 [mu] g of selenoprotein or organic selenium yeast, and a capsule carrier comprises 100 mg of gelatin or a plant-derived capsule shell, 180 mg of microcrystalline cellulose, 5 mg of magnesium stearate and 5 mg of silicon dioxide.

The present application provides a nucleoside derivative gel-forming ability prediction model based on machine learning, and belongs to the field of computer prediction systems. Based on feature selection, hyperparameter optimization and algorithm comparison, the present application successfully establishes an optimal machine model for predicting the hydrogel formation ability of nucleoside derivatives. The model can effectively predict whether nucleoside derivatives have gel-forming ability. Furthermore, the present application selects 12 nucleoside gelling agents with greater possibility from the model, and verifies their hydrogel formation ability through experiments. Among them, 10 nucleoside derivatives can form hydrogels, and the success rate of forming hydrogels is 83.33%, indicating that the nucleoside derivative gel-forming ability prediction model of the present application has high prediction accuracy. The machine model of the present application provides a tool for predicting nucleoside derivatives with hydrogel formation ability.

Oligomeric compounds (including those that are antisense agents or portions thereof) are provided that comprise a modified oligonucleotide having at least one modified internucleoside linking group.SOLUTION: By an oligomeric compound comprising a modified oligonucleotide consisting of 12 to 70 linked nucleosides linked via internucleoside linking groups, wherein at least one nucleoside comprises a modified sugar moiety and wherein at least one internucleoside linking group is a phosphodiester or phosphorothioate internucleoside linking group.SELECTED DRAWING: Figure 1

The present invention belongs to the technical field of medicine and provides a carbocyclic nucleoside-containing siRNA conjugate, and a pharmaceutical composition and a use thereof. The sense strand and / or antisense strand of the siRNA conjugate comprises at least one carbocyclic nucleoside represented by structural formula (I) below. The sense strand comprises at least 16 consecutive nucleotides of the nucleotide sequence 5'-GUCAUCCACAAUGAGAGUACA-3', and the antisense strand comprises at least 18 consecutive nucleotides of the nucleotide sequence 5'-UGUACUCUCAUUGUGGAUGACGA-3'. The carbocyclic nucleoside-containing siRNA conjugate provided by the present invention can be used for treating, preventing, and / or alleviating AGT-related diseases, such as hypertension.

Described herein are modified RNA molecules where a 3′-stabilizing region is covalently attached to the RNA, and where the 3′-stabilizing region comprises one or more modified nucleosides. Methods of synthesizing said RNAs are also provided herein.

The invention relates to the technical field of dye separation, and discloses a loose nanofiltration membrane and a preparation method and application thereof, the loose nanofiltration membrane comprises a porous support membrane, and a polyesteramide separation layer formed on the porous support membrane through one-step interfacial polymerization of nucleoside monomers and multi-acyl chloride monomers. The nucleoside monomer is one or more than two of adenosine, guanosine and cytidine nucleoside. The nucleoside monomer with a long-chain structure, a branched-chain structure, a rigid twisted structure and a plurality of hydrophilic reaction sites is selected as an interfacial polymerization water-phase monomer, so that the loose nanofiltration membrane is endowed with excellent permeation and separation performance. The membrane has a high rejection rate on dye molecules such as Congo red and methyl blue, also has high water permeability and extremely high dye / inorganic salt separation selectivity, and shows good application potential in the aspects of dye production and purification and dye wastewater recovery.

The present disclosure provides methods for preparing oligonucleotides. In certain embodiments, the present disclosure provides methods for preparing oligonucleotides using cyclic-phosphate or cyclic-thiophosphate nucleosides. In certain embodiments, the present disclosure provides methods for preparing oligonucleotides using nucleophiles selected from substituted thiol nucleophiles, substituted nitrogen-based nucleophiles, substituted phosphine nucleophiles, halides, pseudohalides, azides, and substituted lithium-based nucleophiles.

[Problem to be Solved] To provide a novel method for producing a 2'-carbamoylalkyl-modified nucleoside having a pyrimidine base. [Solution] A method for producing a 2'-carbamoylalkyl-modified uridine compound characterized by reacting an anhydrouridine compound and an amide compound having a protected or unprotected hydroxy group in a solvent such as an ether solvent in the presence of a boron reagent, and a method for producing a 2'-carbamoylalkyl-modified cytidine compound including a step of converting a uracil base of a 2'-carbamoylalkyl-modified uridine compound into a cytosine base.

This invention relates to a pharmaceutical composition for tumor treatment and its application. Specifically, this invention relates to a composition containing a fluorouracil drug and pyrimidine nucleosides and their derivatives. Fluorouracil drugs and pyrimidine nucleotides and their derivatives have a synergistic antitumor effect; combined use can reduce the concentration of single drugs and achieve better antitumor efficacy, while reducing toxic side effects.

The present invention relates to 2'-fluoro-6'-methylene carbocyclic nucleosides and nucleotides, pharmaceutical compositions containing these nucleosides and nucleotides, and their use in the treatment or prophylaxis of poxvirus infections and secondary disease states and conditions thereof.

The present invention provides compositions for the prevention and treatment of genital herpes, comprising nucleoside modified mRNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.

The invention provides a nucleoside phosphoramidite compound as shown in a formula I. The invention further provides a preparation method of the nucleoside phosphoramidite compound. The nucleoside phosphoramidite compound disclosed by the invention can be introduced into the head and tail ends and / or the middle of oligonucleotide, the stability of the oligonucleotide is enhanced while the biological function of the oligonucleotide is enhanced or basically maintained, and the continuous acting time is prolonged.

The present application relates to a crystal form of a compound of formula (I) and a preparation method and application thereof. Specifically, the present application provides a crystal form of a compound of formula (I), which has good stability, good drug efficacy, and good safety, and can be used for preparing a drug for treating or preventing feline transmissible enteric disease virus infection or coronavirus infection caused diseases.

This invention relates to the field of skincare technology, and in particular to a method for extracting active components from silkworm pupae and a moisturizing facial mask composition. The extraction method includes: freezing, grinding, and sieving silkworm pupae to obtain silkworm pupae powder; defatting the silkworm pupae powder in an ethanol solution and filtering to obtain defatted silkworm pupae powder; mixing the defatted silkworm pupae powder, water, and neutral protease, adjusting the pH to 6.2-7.0, and sequentially performing enzymatic hydrolysis, enzyme inactivation, centrifugation, and filtration to obtain an enzymatic hydrolysate; centrifuging, microfiltration, and fine filtration of the enzymatic hydrolysate to obtain the active components of silkworm pupae. This invention, through the synergistic effect of freezing and enzymatic hydrolysis, releases small molecule peptides, amino acids, and nucleoside active substances from silkworm pupae under mild conditions, reducing the risk of protein denaturation and inactivation; through a step-by-step physical impurity removal chain of centrifugation, microfiltration, and fine filtration, large molecule sensitizing proteins are removed without introducing organic solvents, making it more suitable for skincare products.

This invention relates to a method for quantifying mRNA capping efficiency, the method comprising mixing a sample, an enzyme mixture, and an isotope standard solution in a buffer solution to produce an incubation mixture, the enzyme mixture comprising a nonspecific single-stranded nuclease and an acid phosphatase, and the isotope standard comprising isotopically labeled m7G and isotopically labeled 2'-O-methylated nucleoside; incubating the mixture; and analyzing the mixture using liquid chromatography-mass spectrometry to determine at least one of capping efficiency and 2-O-methyltransferase efficiency.

This application relates to the field of maize technology, specifically to the ZmPAR1 gene and its applications. A gene encoding a nucleoside kinase was discovered in the maize genome. This nucleoside kinase was obtained through in vitro recombinant expression of the encoded gene. Testing revealed that this nucleoside kinase exhibits binding activity to various nucleoside substrates and can catalyze the synthesis of monophosphate nucleotides from nucleosides. This gene influences maize plant height, leaf angle, ear height, leaf length, and leaf width. Knocking down or overexpressing this gene can yield new maize materials, providing technical support for the breeding of new maize materials and the construction of germplasm resources.

The application discloses a method for producing deoxythymidine triphosphate by using a recombinant strain, and comprises the following steps: step 1: using a CRISPR / Cas9-mediated gene editing method to perform targeted modification on an E. coli genome, and the targeted modification comprises the following contents: a. knocking out a nucleoside triphosphate pyrophosphatase gene (mazG / yhdE) to block a path of degrading dTTP into dTMP; b. knocking out a nucleotide nucleosidase gene (ppnN) to block a path of degrading dTMP into thymine; and c. knocking out a nucleotidase gene (yfbR / yfdR / ushA / umpH / umpG / yjjG) to block a path of degrading dTMP into dT. The application provides a method for producing deoxythymidine triphosphate by using a recombinant strain, and the conversion rate of the method reaches 80% to 90%, and after ion exchange chromatography purification, the purity can reach more than 99%.

The present application provides a kind of synthesis method of nucleoside intermediate compound, the nucleoside intermediate has the structure shown in formula I, its synthetic route is as follows: wherein, the definition of each substituent group is defined in the specification.The compound of formula II in the present application is prepared by reaction in the presence of base and catalyst to obtain the compound of formula I, which overcomes the defects of many by-products and low yield in the prior art, and has good application prospect.

Provided is a novel technique for linking polypeptide domains. Provided is a composite substance comprising a polypeptide domain A, a polymer, and a polypeptide domain B, wherein the polymer comprises non-amino acid monomer units linked by internucleoside bonds, and the polypeptide domain A and the polypeptide domain B are linked via the polymer.

The invention relates to the technical field of plant genetic engineering, and discloses application of a knockout rice OsWAK55 gene in improvement of drought resistance and salt resistance of rice. According to the invention, a candidate gene is subjected to CRISPR (clustered regularly interspaced short palindromic repeats) knockout, a mutant is subjected to phenotype identification and stress screening, the gene OsWAK55 for regulating and controlling rice drought and salt stress is cloned, a nucleoside sequence of the gene OsWAK55 is shown as SEQ ID NO: 1, and a protein sequence coded by the gene is shown as SEQ ID NO: 2. A stress experiment in the seedling stage of the mutant shows that after the gene is mutated, the drought resistance and the salt resistance of the rice are enhanced, and the enhancement of the drought resistance is related to the condition that the mutant seedling has a more developed and robust root system. Therefore, the gene OsWAK55 is knocked out, so that the improvement of the abiotic stress resistance of the rice is facilitated.

The application provides a preparation method and intermediates of 5'-nucleoside prodrugs. Specifically, the application provides a method for preparing a compound of formula VI, the method comprising the steps of: (a) reacting a compound of formula I with a compound of formula II to obtain a compound of formula III; (b) reacting the compound of formula III with a reagent M to obtain a compound of formula IV; (c) reacting the compound of formula IV in the presence of a reagent N to obtain a compound of formula V; and (d) reacting the compound of formula V with a reagent O to obtain the compound of formula VI. The preparation method has the advantages of low cost, high yield and good product purity, and can realize efficient synthesis of 5'-nucleoside prodrugs.

The present invention relates to amino acid salts of nicotinic acid ribosides and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+:wherein M1, R1, R2, and R3 are as described herein.

The invention belongs to the technical field of molecular biology breeding, and particularly relates to application of nucleoside diphosphate kinase GhNDPK9 in promoting salt tolerance of cotton. The amino acid sequence of the protein coded by the GhNDPK9 gene is as shown in SEQ ID NO. 2. The invention discloses the effect of the GhNDPK9 gene in positive regulation and control of the salt tolerance of the cotton, enriches functional genes for salt-tolerant cotton breeding, and provides a new effective way for genetic improvement of salt stress resistance of the cotton. By means of transgenic genetic breeding, the expression level of the GhNDPK9 gene is improved, damage symptoms of plants under the salt stress condition are relieved, the salt tolerance of the plants is enhanced, and then the viability of cotton on salinized soil is improved; the method has wide application prospects and good social benefits in the aspects of genetic improvement of salt-tolerant new germplasm, widening of the suitable planting range of cotton and the like.

Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2′-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

The invention provides a synthesis method of a nucleoside intermediate compound, the nucleoside intermediate has a structure as shown in formula I, and the synthesis route is as follows: each substituent group is defined in the specification. The compound shown in the formula II reacts in the presence of alkali and the catalyst to prepare the compound shown in the formula I, so that the defects of more reaction byproducts and low yield in the prior art are overcome, and the compound shown in the formula II has a relatively good application prospect.

Therapeutic methods and pharmaceutical compositions for treating a myeloproliferative neoplasm (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis, are described. In certain embodiments, the invention includes therapeutic methods of treating a MPN using a combination of a compound of Formula (I) or Formula (II) with a therapeutic agent selected from the group consisting of a JAK inhibitor, an IDH inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, a PD-L2 inhibitor, an interferon, a PI3K inhibitor, an AKT inhibitor, an mTOR inhibitor, a nucleoside analog, and combinations thereof.

The invention discloses a multi-mode liquid chromatography filler of ionic liquid hydrogel modified silica gel and preparation and application thereof, and the method comprises the following steps: fully dissolving an ionic liquid hydrogel monomer and a cross-linking agent in a polar aprotic organic solvent, adding silica gel, carrying out ultrasonic treatment, and standing; adding an initiator, stirring, condensing, refluxing, stirring and reacting at 70-80 DEG C in an inert atmosphere; and drying under stirring, centrifugally washing and drying. According to the invention, the problems of single functional group, tedious modification steps, low ligand density and poor high-pressure stability in the existing method are solved. The preparation method is simple and convenient, efficient modification of hydrogel on the surface of silica gel can be achieved, and the prepared liquid chromatography packing has good separation selectivity on nucleoside / basic groups, organic acid compounds, alkaloid, antibiotics, aniline compounds, anion-containing compounds and the like; and chromatographic separation in a hydrophilic chromatographic mode, a hydrophobic chromatographic mode and an ion exchange chromatographic mode can be realized.

The present invention provides: a compound which is an antisense oligonucleotide capable of regulating the expression of a RasGRP4 gene and treating myositis and rheumatoid arthritis, and which has a nucleic acid base sequence consisting of 8-80 linked nucleosides and comprising at least 8 consecutive nucleic acid bases complementary to a transcript of RasGRP4; or a pharmacologically acceptable salt thereof.